Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers observed elevated levels of epidermal γδ T cells, keratinocytes, and an upregulation of the BST2 gene among immune cells in C3H/HeJ mice with alopecia areata, suggesting a potential role in disease pathogenesis.

Reducing CD8+ T cell growth can stabilize alopecia areata.

In this study, researchers found that ex vivo and in vivo administration of the TYK2 inhibitor BMS-986202 prevented immune privilege collapse and promoted hair regrowth in models of alopecia areata, suggesting this approach may offer a new therapeutic avenue deserving of clinical investigation.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.

This research explored the roles of various T cell types in chronic alopecia areata, finding that increased severity of lesions and hair loss may be linked to decreased lesional Foxp3+ Tregs, with a notable role for IL-17 and Th17 lymphocytes in the pathological process.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

This study found that in chronic alopecia areata, increased IL-17 expression and CD8+CD49a-Trm cell infiltration in hair follicles were associated with more severe histopathologic gradings, while Foxp3+mTreg infiltration decreased.

This study suggests that in alopecia areata, innate lymphoid cells type 1 may contribute to the disease’s pathogenesis by inducing hair follicle changes similarly to CD8+ T cells.

This paper discusses two preclinical models for studying alopecia areata and finds that testing new therapeutic agents should involve both the C3H/HeJ mouse model and the humanized mouse model for comprehensive insights.

This review discusses the current status of genetic research on male-pattern hair loss and reports no new findings, outlining significant achievements and future challenges in understanding its biology and treatment.

This study found that adipose derived stem cells in areas of alopecia in patients with androgenetic alopecia showed different levels of various signaling proteins compared to other scalp and periumbilical regions.

Many medications can cause hair loss or excessive hair growth, which is usually reversible after stopping the drug.

This review discusses the complexities of hidradenitis suppurativa pathogenesis, highlighting issues with Notch signaling, immune dysregulation, and the role of keratinocytes and ECM, but reports no new clinical results.

This article reviews various drugs reported to cause alopecia, including cytostatics and anticoagulants, but does not present new research results; it suggests that drug-related hair loss can be difficult to prove.

This review discusses the various common, rare, and unusual skin manifestations of lupus erythematosus and highlights the importance of accurate diagnosis, but it reports no new clinical results.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This study found that type I interferon response-related genes activated by RIG-1 and IL-17 pathways were significantly up-regulated in hair follicle and skin samples with chronic discoidal lupus erythematosus.

In this study, IFN-γ-stimulated iPSC-derived mesenchymal stem cell extracellular vesicles improved atopic dermatitis in mice by reducing Th2 cytokine activity, suppressing inflammation, and restoring skin barrier function, as evidenced by decreased itching and inflammatory markers.

This review discusses current and emerging treatments for discoid lupus erythematosus, suggesting that new biologic and small-molecule therapies may improve disease control when combined with traditional management.

This review compares various rodent models that reflect aspects of psoriasis with human psoriasis and potential applications for research, reporting no new clinical findings.

This review discusses strategies to enhance mesenchymal stem cell therapy effectiveness but reports no new clinical results; it highlights the need for improved consistency and efficacy in MSC-based treatments.

This study found that antroquinonol inhibited CD8+ T cell proliferation and reduced proinflammatory cytokine secretion in vitro, while also ameliorating H2O2-induced depigmentation and resisting reductions in hair follicle length, skin thickness, and tyrosinase expression in mice.

This study found that several anti-cancer agents strongly inhibit DNA synthesis in human hair germinative cells, while certain cytokines showed only slight inhibition.

In this animal study, a herbal preparation demonstrated moderate anti-inflammatory and immunomodulating properties, suggesting its potential usefulness for preventing and treating alopecia.

This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.

In this study, researchers observed that a topical gel containing 20% hypoxia mesenchymal stem cell secretome significantly reduced IL-15 and IFN-γ mRNA expression and baldness by 60% in male Wistar rats with fluconazole-related alopecia.

This review discusses the roles of various growth factors and cytokines in skin regeneration, highlighting their potential for future therapeutic development, and reports no new experimental findings.

This case report describes a 79-year-old woman who developed alopecia universalis shortly after recovering from COVID-19, highlighting its relapsing nature and the challenges in long-term disease management.